Pfizer presents Phase 3 safety and immunogenicity data on Prevenar 13 in adults aged 18 to 49 years
28 April 2013 | By Pfizer
Pfizer presented the results from a Phase 3 study...
List view / Grid view
28 April 2013 | By Pfizer
Pfizer presented the results from a Phase 3 study...
25 April 2013 | By Pfizer
Pfizer intends to appeal and seek re-examination...
10 April 2013 | By Pfizer
Palbociclib has received Breakthrough Therapy designation...
3 April 2013 | By Pfizer
CHOP and Pfizer are joining forces...
28 March 2013 | By Pfizer
“I’m delighted the EC has approved BOSULIF..."
25 March 2013 | By Pfizer
“RA is a serious and disabling disease and there is a need for new treatment options..."
10 March 2013 | By Pfizer
Results from the REMINDER trial...
4 March 2013 | By Pfizer
Pfizer presented the results from a Phase 3 study...
5 February 2013 | By Abzil BioVigilant
This webinar offers insight from both an end user and a supplier in order to share with you compelling reasons to consider the use of RMMs to gain a better understanding of your environment while improving your competitive advantage...
25 January 2013 | By Pfizer
Prevnar 13 is the first and only pneumococcal conjugate vaccine approved for this age group...
24 January 2013 | By Pfizer
New data add to evidence supporting PRISTIQ as a treatment option for MDD...
22 January 2013 | By Pfizer
Pfizer celebrates 10th anniversary of this signature social investment program...
18 January 2013 | By Pfizer
“We are very pleased with this positive recommendation on bosutinib by the CHMP..."
14 January 2013 | By Pfizer
Quillivant XR™ CII for extended-release oral suspension is now available...
3 January 2013 | By EMD Serono; Pfizer Inc.
The majority of patients found Rebif Rebidose easy to use in a user trial...